CAG
AVEO

Crestwood Advisors Group’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Crestwood Advisors Group’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-506
Closed -$3K – 481
2017
Q1 		$3K Buy
+506
New +$3.65K ﹤0.01% 500
2015
Q1 		– Sell
-1,506
Closed -$13K – 163
2014
Q4 		$13K Buy
+1,506
New +$13.8K ﹤0.01% 144

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Crestwood Advisors Group's AVEO Position: Q2 2017 in Review

Crestwood Advisors Group sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2017, closing a stake of 506 shares — an estimated $3K sold.

Crestwood Advisors Group first reported a position in AVEO in Q4 2014 and held it in 2 quarters. The position peaked at $13K in Q4 2014. 49 funds tracked by Wall St. Rank hold AVEO as of Q2 2017.

  • Crestwood Advisors Group reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Crestwood Advisors Group sold 506 AVEO Pharmaceuticals, Inc. shares in Q2 2017, an estimated $3K.
  • Crestwood Advisors Group first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
  • Crestwood Advisors Group's AVEO Pharmaceuticals, Inc. position peaked at $13K in Q4 2014.
  • 49 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2017.

Based on Crestwood Advisors Group's 13F filing for Q2 2017, filed 31 Jul 2017.